| GL |
Report |
Net operating EPS |
IN-LINE |
pred ~$3.68 vs. cons $3.66 |
MEDIUM |
| GL |
Report |
Life underwriting margin (Q2, normalized) |
IN-LINE |
pred ~41.5% vs. cons ~41.0% |
MEDIUM |
| GL |
Report |
AIL average producing agent count growth (y/y) |
BEAT |
pred ~-1.5% vs. cons ~-3.5% |
LOW |
| GL |
Guide |
FY26 net operating EPS guidance (midpoint) |
UNCHANGED |
guide ~$15.65 vs. cons $15.65 (FY2026) |
MEDIUM |
| GL |
Guide |
FY26 life underwriting margin guidance (midpoint) |
UNCHANGED |
guide ~43.5% vs. cons ~43.5% (FY2026) |
MEDIUM |
| GL |
Guide |
Q3 life-margin assumption-update pre-tax benefit |
UNCHANGED |
guide ~$90M vs. cons ~$90M (Q3 2026) |
LOW |
| GL |
Guide |
United American/health full-year sales growth |
UNCHANGED |
guide ~17% vs. cons ~17% (FY2026) |
LOW |
| GL |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.2% |
— |
MEDIUM |
| GL |
Return |
5-day cumulative residual |
-5.5% (FADE) |
Stock has rallied ~33% since mid-June into the print (from ~$138 in Jan to ~$184, average analyst PT only ~$188.55), leaving almost no cushion for anything short of a clean beat-and-raise. Q2 is explicitly guided to a 'clean' ~41% normalized life margin with the real upside catalyst (Q3 assumption-update benefit) withheld until next quarter, so an in-line Q2 print with only reaffirmed (not raised) FY26 guidance removes the near-term re-rating catalyst investors have been front-running. Precedent from Q1 (a small EPS miss that the market shrugged off only because guidance was raised) suggests a merely reaffirmed guide this time, after such a steep run-up and with AIL agent-count recovery still unconfirmed, likely triggers sell-the-news profit-taking that builds over the week as sell-side analysts trim near-term numbers pending the Q3 assumption update, rather than an immediate one-day-and-done reaction. |
MEDIUM |